Other Immunological Disorders – Pipeline Review, H2 2012
出 版 商：Global Markets Direct
出版日期：2012/08/31
頁 數：55頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Other Immunological Disorders – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Other Immunological Disorders - Pipeline Review, H2 2012', provides an overview of the Other Immunological Disorders therapeutic pipeline. This report provides information on the therapeutic development for Other Immunological Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Other Immunological Disorders. 'Other Immunological Disorders - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Other Immunological Disorders.
- A review of the Other Immunological Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Other Immunological Disorders pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Other Immunological Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Other Immunological Disorders pipeline depth and focus of Other Immunological Disorders therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Summary
Global Markets Direct’s, 'Other Immunological Disorders - Pipeline Review, H2 2012', provides an overview of the Other Immunological Disorders therapeutic pipeline. This report provides information on the therapeutic development for Other Immunological Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Other Immunological Disorders. 'Other Immunological Disorders - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Other Immunological Disorders.
- A review of the Other Immunological Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Other Immunological Disorders pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Other Immunological Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Other Immunological Disorders pipeline depth and focus of Other Immunological Disorders therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Other Immunological Disorders Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Other Immunological Disorders 8
Other Immunological Disorders Therapeutics under Development by Companies 10
Other Immunological Disorders Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Discovery and Pre-Clinical Stage Products 16
Comparative Analysis 16
Other Immunological Disorders Therapeutics – Products under Development by Companies 17
Other Immunological Disorders Therapeutics – Products under Investigation by Universities/Institutes 18
Companies Involved in Other Immunological Disorders Therapeutics Development 19
Daiichi Sankyo Company, Ltd 19
ALS Therapy Development Institute 20
Omeros Corporation 21
Ampio Pharmaceuticals, Inc. 22
Other Immunological Disorders – Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
CS-0777 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
MGA031 + Sirolimus + Tacrolimus - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 31
Enbrel - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Busulfan + Cyclophosphamide + Antithymocyte Globulin + Hematopoietic Stem Cell Transplantation - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Gamunex - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
DMI-9523 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Fludarabine + Busulfan + Alemtuzumab + Allogeneic Stem Cell Transplantation - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Micafungin - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Campath 1H + Fludarabine - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
posaconazole (PSZ) - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Abine Phosphate + Thiotepa + Allogeneic Bone Marrow Transplantation - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 43
Project TDI 173 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Drug targeting CCRL2 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Other Immunological Disorders Therapeutics – Discontinued Products 46
Other Immunological Disorders Therapeutics - Dormant Products 47
Other Immunological Disorders – Product Development Milestones 48
Featured News & Press Releases 48
Aug 16, 2011: Octapharma Receives Australian Approval For Resupply Of Octagam 48
Jan 05, 2011: Amira Announces Publication Of AM095 Preclinical Results In Journal Of Pharmacology And Experimental Therapeutics 48
Sep 24, 2010: Update Of Product Withdrawal/Product Recall Octopharm's Octagam 10% (octagam 100mg/ml) 49
Aug 05, 2010: YM BioSciences Announces Conclusion Of Phase I Dose-Escalation And Expansion Of Ongoing CYT387 Phase I/II Clinical Study 50
Aug 04, 2010: XOMA Receives FDA Orphan Drug Designation For XOMA 052 For Treatment Of Behcet's Disease 51
Jun 17, 2010: XOMA Presents Positive Clinical Findings Of XOMA 052 In Patients With Uveitis Of Behcet's Disease 51
Sep 24, 2009: Octapharma submits BLA To US FDA For Octagam 10% 52
Nov 10, 2008: Gene Signal Enters Phase III Clinical Tests For The Prevention Of Corneal Graft Rejection 53
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 55
Disclaimer 55
List of Tables
Number of Products Under Development for Other Immunological Disorders, H2 2012 8
Products under Development for Other Immunological Disorders – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Early Clinical Stage Development, H2 2012 15
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 16
Products under Development by Companies, H2 2012 17
Products under Investigation by Universities/Institutes, H2 2012 18
Daiichi Sankyo Company, Ltd, H2 2012 19
ALS Therapy Development Institute, H2 2012 20
Omeros Corporation, H2 2012 21
Ampio Pharmaceuticals, Inc., H2 2012 22
Assessment by Monotherapy Products, H2 2012 23
Assessment by Combination Products, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 28
Other Immunological Disorders Therapeutics – Discontinued Products 46
Other Immunological Disorders Therapeutics – Dormant Products 47
List of Figures
Number of Products under Development for Other Immunological Disorders, H2 2012 8
Products under Development for Other Immunological Disorders – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Early Clinical Stage Products, H2 2012 15
Discovery and Pre-Clinical Stage Products, H2 2012 16
Assessment by Monotherapy Products, H2 2012 23
Assessment by Combination Products, H2 2012 24
Assessment by Route of Administration, H2 2012 25
Assessment by Stage and Route of Administration, H2 2012 26
Assessment by Molecule Type, H2 2012 27
Assessment by Stage and Molecule Type, H2 2012 28
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Other Immunological Disorders Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Other Immunological Disorders 8
Other Immunological Disorders Therapeutics under Development by Companies 10
Other Immunological Disorders Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Discovery and Pre-Clinical Stage Products 16
Comparative Analysis 16
Other Immunological Disorders Therapeutics – Products under Development by Companies 17
Other Immunological Disorders Therapeutics – Products under Investigation by Universities/Institutes 18
Companies Involved in Other Immunological Disorders Therapeutics Development 19
Daiichi Sankyo Company, Ltd 19
ALS Therapy Development Institute 20
Omeros Corporation 21
Ampio Pharmaceuticals, Inc. 22
Other Immunological Disorders – Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
CS-0777 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
MGA031 + Sirolimus + Tacrolimus - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 31
Enbrel - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Busulfan + Cyclophosphamide + Antithymocyte Globulin + Hematopoietic Stem Cell Transplantation - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Gamunex - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
DMI-9523 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Fludarabine + Busulfan + Alemtuzumab + Allogeneic Stem Cell Transplantation - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Micafungin - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Campath 1H + Fludarabine - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
posaconazole (PSZ) - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Abine Phosphate + Thiotepa + Allogeneic Bone Marrow Transplantation - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 43
Project TDI 173 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Drug targeting CCRL2 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Other Immunological Disorders Therapeutics – Discontinued Products 46
Other Immunological Disorders Therapeutics - Dormant Products 47
Other Immunological Disorders – Product Development Milestones 48
Featured News & Press Releases 48
Aug 16, 2011: Octapharma Receives Australian Approval For Resupply Of Octagam 48
Jan 05, 2011: Amira Announces Publication Of AM095 Preclinical Results In Journal Of Pharmacology And Experimental Therapeutics 48
Sep 24, 2010: Update Of Product Withdrawal/Product Recall Octopharm's Octagam 10% (octagam 100mg/ml) 49
Aug 05, 2010: YM BioSciences Announces Conclusion Of Phase I Dose-Escalation And Expansion Of Ongoing CYT387 Phase I/II Clinical Study 50
Aug 04, 2010: XOMA Receives FDA Orphan Drug Designation For XOMA 052 For Treatment Of Behcet's Disease 51
Jun 17, 2010: XOMA Presents Positive Clinical Findings Of XOMA 052 In Patients With Uveitis Of Behcet's Disease 51
Sep 24, 2009: Octapharma submits BLA To US FDA For Octagam 10% 52
Nov 10, 2008: Gene Signal Enters Phase III Clinical Tests For The Prevention Of Corneal Graft Rejection 53
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 55
Disclaimer 55
List of Tables
Number of Products Under Development for Other Immunological Disorders, H2 2012 8
Products under Development for Other Immunological Disorders – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Early Clinical Stage Development, H2 2012 15
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 16
Products under Development by Companies, H2 2012 17
Products under Investigation by Universities/Institutes, H2 2012 18
Daiichi Sankyo Company, Ltd, H2 2012 19
ALS Therapy Development Institute, H2 2012 20
Omeros Corporation, H2 2012 21
Ampio Pharmaceuticals, Inc., H2 2012 22
Assessment by Monotherapy Products, H2 2012 23
Assessment by Combination Products, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 28
Other Immunological Disorders Therapeutics – Discontinued Products 46
Other Immunological Disorders Therapeutics – Dormant Products 47
List of Figures
Number of Products under Development for Other Immunological Disorders, H2 2012 8
Products under Development for Other Immunological Disorders – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Early Clinical Stage Products, H2 2012 15
Discovery and Pre-Clinical Stage Products, H2 2012 16
Assessment by Monotherapy Products, H2 2012 23
Assessment by Combination Products, H2 2012 24
Assessment by Route of Administration, H2 2012 25
Assessment by Stage and Route of Administration, H2 2012 26
Assessment by Molecule Type, H2 2012 27
Assessment by Stage and Molecule Type, H2 2012 28
